- Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
- Veracyte to Participate in Upcoming Investor Conferences
- Veracyte Announces First Quarter 2024 Financial Results
- 14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
- Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
- New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
- Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
More ▼
Key statistics
On Friday, Veracyte Inc (VCYT:NMQ) closed at 20.75, 11.50% above the 52 week low of 18.61 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.10 |
---|---|
High | 21.40 |
Low | 20.69 |
Bid | 20.65 |
Offer | 24.00 |
Previous close | 20.99 |
Average volume | 650.98k |
---|---|
Shares outstanding | 76.45m |
Free float | 75.80m |
P/E (TTM) | -- |
Market cap | 1.59bn USD |
EPS (TTM) | -0.9346 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼